Recanalisation theraphy for acute ischemic stroke in cancer patients

Abstract To date, very few studies focused their attention on efficacy and safety of recanalisation therapy in acute ischemic stroke (AIS) patients with cancer, reporting conflicting results. We retrospectively analysed data from our database of consecutive patients admitted to the Udine University...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giovanni Merlino, Carmelo Smeralda, Gian Luigi Gigli, Simone Lorenzut, Sara Pez, Andrea Surcinelli, Alessandro Marini, Valentina Maniaci, Mariarosaria Valente
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/11f07af28bb448968101021bad8c3d71
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:11f07af28bb448968101021bad8c3d71
record_format	dspace
spelling	oai:doaj.org-article:11f07af28bb448968101021bad8c3d712021-12-02T17:51:06ZRecanalisation theraphy for acute ischemic stroke in cancer patients10.1038/s41598-021-91257-52045-2322https://doaj.org/article/11f07af28bb448968101021bad8c3d712021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91257-5https://doaj.org/toc/2045-2322Abstract To date, very few studies focused their attention on efficacy and safety of recanalisation therapy in acute ischemic stroke (AIS) patients with cancer, reporting conflicting results. We retrospectively analysed data from our database of consecutive patients admitted to the Udine University Hospital with AIS that were treated with recanalisation therapy, i.e. intravenous thrombolysis (IVT), mechanical thrombectomy (MT), and bridging therapy, from January 2015 to December 2019. We compared 3-month dependency, 3-month mortality, and symptomatic intracranial haemorrhage (SICH) occurrence of patients with active cancer (AC) and remote cancer (RC) with that of patients without cancer (WC) undergoing recanalisation therapy for AIS. Patients were followed up for 3 months. Among the 613 AIS patients included in the study, 79 patients (12.9%) had either AC (n = 46; 7.5%) or RC (n = 33; 5.4%). Although AC patients, when treated with IVT, had a significantly increased risk of 3-month mortality [odds ratio (OR) 6.97, 95% confidence interval (CI) 2.42–20.07, p = 0.001] than WC patients, stroke-related deaths did not differ between AC and WC patients (30% vs. 28.8%, p = 0.939). There were no significant differences between AC and WC patients, when treated with MT ± IVT, regarding 3-month dependency, 3-month mortality and SICH. Functional independence, mortality, and SICH were similar between RC and WC patients. In conclusion, recanalisation therapy might be used in AIS patients with nonmetastatic AC and with RC. Further studies are needed to explore the outcome of AIS patients with metastatic cancer undergoing recanalisation therapy.Giovanni MerlinoCarmelo SmeraldaGian Luigi GigliSimone LorenzutSara PezAndrea SurcinelliAlessandro MariniValentina ManiaciMariarosaria ValenteNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Giovanni Merlino Carmelo Smeralda Gian Luigi Gigli Simone Lorenzut Sara Pez Andrea Surcinelli Alessandro Marini Valentina Maniaci Mariarosaria Valente Recanalisation theraphy for acute ischemic stroke in cancer patients
description	Abstract To date, very few studies focused their attention on efficacy and safety of recanalisation therapy in acute ischemic stroke (AIS) patients with cancer, reporting conflicting results. We retrospectively analysed data from our database of consecutive patients admitted to the Udine University Hospital with AIS that were treated with recanalisation therapy, i.e. intravenous thrombolysis (IVT), mechanical thrombectomy (MT), and bridging therapy, from January 2015 to December 2019. We compared 3-month dependency, 3-month mortality, and symptomatic intracranial haemorrhage (SICH) occurrence of patients with active cancer (AC) and remote cancer (RC) with that of patients without cancer (WC) undergoing recanalisation therapy for AIS. Patients were followed up for 3 months. Among the 613 AIS patients included in the study, 79 patients (12.9%) had either AC (n = 46; 7.5%) or RC (n = 33; 5.4%). Although AC patients, when treated with IVT, had a significantly increased risk of 3-month mortality [odds ratio (OR) 6.97, 95% confidence interval (CI) 2.42–20.07, p = 0.001] than WC patients, stroke-related deaths did not differ between AC and WC patients (30% vs. 28.8%, p = 0.939). There were no significant differences between AC and WC patients, when treated with MT ± IVT, regarding 3-month dependency, 3-month mortality and SICH. Functional independence, mortality, and SICH were similar between RC and WC patients. In conclusion, recanalisation therapy might be used in AIS patients with nonmetastatic AC and with RC. Further studies are needed to explore the outcome of AIS patients with metastatic cancer undergoing recanalisation therapy.
format	article
author	Giovanni Merlino Carmelo Smeralda Gian Luigi Gigli Simone Lorenzut Sara Pez Andrea Surcinelli Alessandro Marini Valentina Maniaci Mariarosaria Valente
author_facet	Giovanni Merlino Carmelo Smeralda Gian Luigi Gigli Simone Lorenzut Sara Pez Andrea Surcinelli Alessandro Marini Valentina Maniaci Mariarosaria Valente
author_sort	Giovanni Merlino
title	Recanalisation theraphy for acute ischemic stroke in cancer patients
title_short	Recanalisation theraphy for acute ischemic stroke in cancer patients
title_full	Recanalisation theraphy for acute ischemic stroke in cancer patients
title_fullStr	Recanalisation theraphy for acute ischemic stroke in cancer patients
title_full_unstemmed	Recanalisation theraphy for acute ischemic stroke in cancer patients
title_sort	recanalisation theraphy for acute ischemic stroke in cancer patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/11f07af28bb448968101021bad8c3d71
work_keys_str_mv	AT giovannimerlino recanalisationtheraphyforacuteischemicstrokeincancerpatients AT carmelosmeralda recanalisationtheraphyforacuteischemicstrokeincancerpatients AT gianluigigigli recanalisationtheraphyforacuteischemicstrokeincancerpatients AT simonelorenzut recanalisationtheraphyforacuteischemicstrokeincancerpatients AT sarapez recanalisationtheraphyforacuteischemicstrokeincancerpatients AT andreasurcinelli recanalisationtheraphyforacuteischemicstrokeincancerpatients AT alessandromarini recanalisationtheraphyforacuteischemicstrokeincancerpatients AT valentinamaniaci recanalisationtheraphyforacuteischemicstrokeincancerpatients AT mariarosariavalente recanalisationtheraphyforacuteischemicstrokeincancerpatients
_version_	1718379270310461440

Recanalisation theraphy for acute ischemic stroke in cancer patients

Ejemplares similares